Showing 1771-1780 of 6978 results for "".
2017 Tax Cuts and Jobs Act: What You Need to Know
https://practicaldermatology.com/topics/practice-management/2017-tax-cuts-and-jobs-act-what-you-need-to-know--vmyiwowa/18348/OJM Group principal Carole Foos, CPA provides an overview of the Tax Cuts and Jobs Act, which was signed in to law at the end of 2017. She discusses key provisions affecting individual physicians and medical practices, and offers advice to consider when planning for 2018 and beyond. Click here to reItch Be Gone
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/itch-be-gone/18524/Could botulinum toxins be the answer for non-histaminergic itch? Erin Gilbert, MD discusses her research in this area and results she's seen to date.Improving Outcomes with Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/improving-outcomes-with-fillers/18740/For the most optimal outcomes when injecting fillers, Dr. Galadari says there are three essential steps: choose the right patient, choose the right filler, and choose the right injection technique. He shares his favorite types of fillers for specific areas and discusses when and why he uses a cannulRestylane Lyft Approved, Analyzing New Quality of Life Data
https://practicaldermatology.com/series/dermwire-tv/dermwire-restylane-lyft-approved-analyzing-new-quality-of-life-data--ibalorid/18878/Restylane Lyft from Galderma approved for mid face volume enhancement, New data analyzes significance of patient quality of life in diseases like psoriasis and atopic dermatitis, Merz North America establishes new headquarters in Raleigh, NC, and Boston unveils free sunscreen dispensers.Radiesse for Hands, Alevicyn Cleared
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-radiesse-for-hands-alevicyn-cleared/18898/Merz gets FDA approval for Radiesse for hand augmentation and releases data comparing Xeomin to Botox. Heidi Waldorf, MD, FAAD and Michael Gold, MD, FAAD, comment. Also in this edition, Galderma participate in a White House forum on antibiotic stewardship, and the FDA gives 510(k) clearance to AleviFacebook Graph Search-An Important Marketing Tool for Doctors
https://practicaldermatology.com/topics/practice-management/facebook-graph-search-an-important-marketing-tool-for-doctors/18931/Graph searching is the latest tool offered by Facebook. Here's what it is and how you can use it in your practice. An Ekwa Marketing Educational video.Implementing Skincare Solutions in Practice
https://practicaldermatology.com/topics/practice-management/implementing-skincare-solutions-in-practice/18902/Leslie Baumann, MD, FAAD discusses the challenges of offering effective skincare recommendations to patients and shares some of the practical solutions she has implemented in her practice. The author of "The Skin Type Solution," describes how she chooses skincare for each individual patient and giveMy Dermatology Wish List
https://practicaldermatology.com/topics/practice-management/my-dermatology-wish-list/18911/What is Dr. Bill Ju's wish for dermatology? The President of Advancing Innovation in Dermatology wants to continue to grow entrepreneurship as a grassroots effort. He'd like to see more support for young ideas and young thinkers.Kythera's Kybella Approved; ASLMS Update
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-kythera-s-kybella-approved-aslms-update/18925/FDA Approves Kythera's Kybella (ATX-101 or deoxycholic acid) injection for reduction of sub mental fullness or double chin. ASLMS Recognizes women in device-based medicine (Women in Energy-based Devices). Deka and Syneron get new clearances. ASDS Launches Skin Cancer PSAs, and Foamix sells shares.The Importance of Skincare
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-importance-of-skincare/19035/Whether patients want lasers, injectables, Botox, or cosmeceuticals, they need guidance on proper skincare to prevent wrinkles and skin cancer, says Dina Anderson, MD, FAAD. Patients need to learn about antioxidants, free radicals, and the effects of smoking.